ERK/p44p42 Mitogen-Activated Protein Kinase Mediates EGF-Stimulated Proliferation of Conjunctival Goblet Cells in Culture

Harvard University, Cambridge, Massachusetts, United States
Investigative ophthalmology & visual science (Impact Factor: 3.66). 05/2008; 49(8):3351-9. DOI: 10.1167/iovs.08-1677
Source: PubMed

ABSTRACT To determine whether activation of the ERK pathway by EGF leads to rat and human goblet cell proliferation.
The conjunctiva was removed from male Sprague-Dawley rats. Human conjunctiva was removed during ocular surgery. The tissue was minced and goblet cells were grown. The cells were stimulated with EGF (10(-7) M) for 1 and 5 minutes and Western blot analysis was performed with an antibody against phosphorylated EGFR, to measure the activation of the EGF receptor (EGFR). The cells were incubated with EGF (10(-7) M) for 24 hours, and cell proliferation was measured by WST-8. Inhibitors were added either 20 minutes before EGF or 2 hours after. The cells were stimulated with EGF (10(-7) M) for 1 minute to 24 hours. The number of cells expressing phosphorylated ERK (pERK) in the nucleus and Ki-67 was determined by immunofluorescence.
EGF increased the activation of EGFR in rat conjunctival goblet cells. EGF-stimulated proliferation was inhibited by the EGFR inhibitor AG1478 and the MEK inhibitor U0126 in rat and human cultured goblet cells. EGF caused the translocation of pERK to the nucleus in a biphasic manner. Inhibition of the second peak with U0126 prevented proliferation. EGF-stimulated goblet cells progressed through the cell cycle expressing pERK in the nucleus.
EGF stimulated human and rat conjunctival goblet cell proliferation by activating the EGFR. EGFR stimulated ERK causing its biphasic translocation to the nucleus. The second peak response is responsible for cell proliferation, but the role of the first peak is not known.

Download full-text


Available from: Robin R Hodges, Jul 29, 2015
  • Source
    • "Proliferation of EPC cultured for 7 days were measured with a Cell Counting Kit-8 (Takeuchi et al., 2003) (Dojindo Molecular Technologies, Gaithersburg, MD, USA) and bromodeoxyuridine (BrdU) assay separately. The tetrazolium compound WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5- (2, 4-disulphophenyl)-2H-tetrazolium, monosodium salt] and an electron coupling reagent were added to the medium to determine the number of viable EPCs (Moriya et al., 2007; Shatos et al., 2008). The tetrazolium compound is bioreduced by cells into a coloured formazan product that is soluble in the tissue culture medium. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Advanced glycation end products (AGEs) and endothelial progenitor cells (EPCs) play key roles in pathogenesis of diabetes-related vascular complications. AGEs can induce dysfunction in EPCs. The peroxisome proliferator-activated receptor-gamma (PPARgamma) agonists are widely used in the treatment of type 2 diabetes, and it remains unknown if they could attenuate EPC dysfunction induced by AGEs. EPCs isolated from healthy adults were cultured with various concentrations of AGEs (0, 50, 100 and 200 mg L(-1)) with or without rosiglitazone (10 nM), antibody for the receptors for AGE-human serum albumin (anti-receptor for advanced glycation end products (RAGE); 50 microg mL(-1)), phosphatidylinositol-3-kinase (PI3K) inhibitor (LY294002, 5 microM), nitric oxide (NO) synthase inhibitor (L-N(G)-nitro-arginine methyl ester (L-NAME), 100 microM) or sodium nitroprusside (SNP, 25 microM). Proliferation, apoptosis, cell adhesion, migration and NO production in EPCs were assessed, and expressions of endothelial NO synthase (eNOS) and Akt were determined. Number, proliferation/migration capacities, eNOS and Akt phosphorylation as well as NO synthesized by EPCs were increased by rosiglitazone and reduced by AGEs. AGEs promoted while rosiglitazone reduced EPC apoptosis. The AGE-induced effects were significantly ameliorated by pre-incubation with rosiglitazone, RAGE antibody and SNP. The beneficial effects of rosiglitazone could be blocked by pretreatment with L-NAME and LY294002. The PPARgamma agonist rosiglitazone increased EPC function and attenuated EPC dysfunction induced by AGEs via upregulating the Akt-eNOS signal pathways of EPCs.
    British Journal of Pharmacology 11/2009; 158(8):1865-73. DOI:10.1111/j.1476-5381.2009.00450.x · 4.99 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The authors determined the role of the protein kinase C (PKC) isoforms cPKCalpha and nPKCepsilon in EGF-stimulated proliferation of cultured rat and human conjunctival goblet cells. Rat and human conjunctivas were minced, and goblet cells were allowed to grow. Passage 1 cells were serum starved for 24 to 48 hours and were incubated with the PKC inhibitors calphostin C and Gö 6983 (10(-10)-10(-7) M) for 20 minutes before stimulation with EGF (10(-7) M) for 24 hours. The presence and localization of PKC isoforms in cultured rat goblet cells were determined by Western blot analysis and immunofluorescence microscopy, respectively. Cultured rat goblet cells were serum starved and incubated with adenoviruses containing genes for dominant-negative cPKCalpha (Ad DNPKCalpha, 10(4) pfu), dominant-negative nPKCepsilon (Ad DNPKCepsilon, 10(4) pfu), and wild-type cPKCalpha (Ad WTPKCalpha, 10(7) pfu), and proliferation was measured. In rat goblet cells, EGF-stimulated proliferation was completely inhibited by calphostin C, whereas Gö 6983 inhibited proliferation by 53%+/-15%. In human goblet cells, EGF-stimulated proliferation was completely inhibited by calphostin C. PKCalpha, -betaI, -betaII, -delta, -epsilon, -iota/lambda, -theta, -gamma, and -zeta were found in cultured rat goblet cells. Ad DNPKCalpha and Ad DNPKCepsilon inhibited EGF-stimulated proliferation in rat goblet cells by 78%+/-6% and 92%+/-8%, respectively. Incubation with Ad WTPKCalpha alone significantly increased proliferation. cPKCalpha and nPKCepsilon play key roles in conjunctival goblet cell proliferation.
    Investigative ophthalmology & visual science 10/2008; 50(2):614-20. DOI:10.1167/iovs.08-2467 · 3.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To determine whether a constitutively active protein kinase C (PKC)-alpha stimulates rat and human conjunctival goblet cell proliferation through activation of ERK 1/2. Conjunctivas from rat and human were minced and goblet cells were allowed to grow. Goblet cells were serum starved and incubated with an adenovirus containing a constitutively active form of PKCalpha (Ad-myr-PKCalpha, 1 x 10(7) pfu), EGF (10(-7) M), or both. The location of myrPKCalpha was determined by immunofluorescence microscopy. Cultured goblet cells were preincubated with the PKC inhibitor calphostin C (10(-10)-10(-7) M) or the ERK 1/2 inhibitor U0126 (10(-9)-10(-6) M) before incubation with Ad-myr-PKCalpha. Cell proliferation was measured. Transduction of rat goblet cells with Ad-myr-PKCalpha did not change PKC location compared with nontransduced cells. Incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.5+/-0.3-fold, whereas EGF increased proliferation by 2.1+/-0.2-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF did not further increase proliferation. U0126 inhibited Ad-myr-PKCalpha-stimulated proliferation a maximum of 70%. In human goblet cells, incubation with Ad-myr-PKCalpha caused an increase in cell proliferation by 2.3+/-0.3-fold, whereas EGF increased proliferation by 3.1+/-0.4-fold. Simultaneous addition of Ad-myr-PKCalpha and EGF decreased proliferation compared with either compound alone. Ad-myr-PKCalpha caused ERK 1/2 to translocate to the nucleus in rat and human cells, but the translocation was blocked by U0126. Activation of PKCalpha alone by inducing phosphorylation of ERK 1/2 and translocating it to the nucleus is necessary and sufficient to cause conjunctival cell proliferation in rat, and probably human, goblet cells.
    Investigative ophthalmology & visual science 04/2009; 50(4):1619-25. DOI:10.1167/iovs.08-2930 · 3.66 Impact Factor
Show more